Suppr超能文献

使用新型功能性报告基因高通量筛选试验鉴定胰高血糖素样肽-1模拟物

Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.

作者信息

Chen Jiaqi, Bai Gang, Yang Yang, Geng Peng, Cao Yu, Zhu Yuanyuan

机构信息

Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 30071, China.

出版信息

Peptides. 2007 Apr;28(4):928-34. doi: 10.1016/j.peptides.2006.12.012. Epub 2006 Dec 27.

Abstract

Glucagon-like peptide-1 (GLP-1) stimulates insulin and inhibits glucagon secretion and therefore could potentially be used to treat diabetes type II. However, its therapeutic use is limited by its short half-life in vivo, due mainly to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Developing GLP-1 analogs with greater bioactivity is therefore an important step toward using them therapeutically. Accordingly, we aimed to identify GLP-1 mimetic peptides by creating a high-throughput screening (HTS) assay of a phage displayed (PhD) peptide library. This assay was functionally based using the GLP-1 receptor (GLP-1R) gene. Rat GLP-1R cDNA was transfected into CHO/enhanced green fluorescent protein (EGFP) cells by lipofection. The resulting stable, recombinant cell line functionally expressed the GLP-1R and a cAMP-responsive EGFP reporter gene, to monitor receptor activation, and was used to screen a PhD dodecapeptide library. After four rounds of selection, 10 positive clones were selected based on functional evaluation and sequenced. Three sequences were obtained, corresponding to three different domains of GLP-1 (Group 1: 22-34; Group 2: 18-29; and Group 3: 6-17). The Group 3 peptide had the highest bioactivity, was synthesized, and designated KS-12. Importantly, KS-12 activated GLP-1R in vitro and reduced blood glucose levels in a dose-dependent manner when administered to Chinese Kunming mice. Although KS-12 was not as effective as GLP-1, it was significantly resistant to DPP-IV both in vitro and in vivo. Thus, this study provides a novel way to screen DPP-IV resistant agonist peptides of GLP-1 from a PhD peptide library using the functional reporter gene HTS assay.

摘要

胰高血糖素样肽-1(GLP-1)可刺激胰岛素分泌并抑制胰高血糖素分泌,因此有可能用于治疗2型糖尿病。然而,其在体内的半衰期较短,主要由于二肽基肽酶IV(DPP-IV)的酶促降解作用,限制了它的治疗用途。因此,开发具有更高生物活性的GLP-1类似物是将其用于治疗的重要一步。相应地,我们旨在通过对噬菌体展示(PhD)肽库进行高通量筛选(HTS)试验来鉴定GLP-1模拟肽。该试验基于GLP-1受体(GLP-1R)基因进行功能检测。通过脂质转染将大鼠GLP-1R cDNA转染至CHO/增强型绿色荧光蛋白(EGFP)细胞中。所得稳定的重组细胞系功能性表达GLP-1R和一个cAMP反应性EGFP报告基因,用于监测受体激活情况,并用于筛选PhD十二肽库。经过四轮筛选后,基于功能评估选择了10个阳性克隆并进行测序。获得了三个序列,分别对应GLP-1的三个不同结构域(第1组:22-34;第2组:18-29;第3组:6-17)。第3组肽具有最高的生物活性,合成后命名为KS-12。重要的是,KS-12在体外可激活GLP-1R,给中国昆明小鼠给药时可剂量依赖性降低血糖水平。虽然KS-12不如GLP-1有效,但在体外和体内对DPP-IV均具有显著抗性。因此,本研究提供了一种利用功能报告基因HTS试验从PhD肽库中筛选GLP-1的DPP-IV抗性激动剂肽的新方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验